Natalia Bello

机构：Eli Lilly (United States) · ORCID：0000-0001-5042-9460

发表论文 58 篇 · 总被引 873 次 · h-index 15

代表论文

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database (2021 · Annals of the Rheumatic Diseases · 被引 167)
Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis (2022 · Lupus · 被引 77)
Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus (2022 · Rheumatology and Therapy · 被引 44)
A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus (2022 · Rheumatology and Therapy · 被引 29)
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy (2022 · RMD Open · 被引 28)
Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis (2020 · Lupus Science & Medicine · 被引 27)